Form 4: Recursion Pharmaceuticals Insider Tax Withholding
Statement of Changes in Beneficial Ownership
Chief Scientific Officer David Hallett disposed of 26,657 shares of Recursion Pharmaceuticals to satisfy tax obligations.
Summary
- David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals, Inc. (RXRX), executed a transaction on May 15, 2026.
- The transaction involved the disposal of 26,657 shares of Class A Common Stock at a price of $3.04 per share.
- The disposal was a mandatory tax withholding event related to the net settlement of restricted stock units (RSUs).
- Following this transaction, the reporting person maintains beneficial ownership of 1,070,494 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine tax-related transaction rather than a strategic shift or market-driven divestment.
Positives
- The transaction was a routine administrative action for tax compliance rather than a discretionary market sale.
- The reporting person retains a significant equity stake of over 1 million shares, aligning interests with shareholders.
Negatives
- The transaction resulted in a reduction of the reporting person's direct share ownership.
Risks
- Reliance on equity-based compensation may lead to periodic selling pressure during tax settlement events.
Future Outlook
No forward-looking guidance or strategic outlook was provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that net settlement of RSUs is a standard industry practice for biotech executives to manage tax liabilities associated with equity vesting, and this filing does not signal a change in corporate strategy or executive confidence.
Comparison to Industry Standards
- The use of net settlement for tax obligations is consistent with standard executive compensation practices across the pharmaceutical and biotechnology sectors.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was a non-discretionary tax settlement.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Date of the reported transaction involving share disposal. |
| 05/18/2026 | Date of filing for the Form 4 statement. |
Keywords
RXRX, Recursion Pharmaceuticals, Insider Trading, Form 4, Biotech, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.